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Precis for use in the Table of Contents: In this study, pathogenic germline mutations in cancer-
predisposing genes, predominantly involved in the DNA damage repair pathway, were found in a 
significant minority of a selected population of men with prostate cancer and at least one other 
primary malignancy. The majority of the men with germline mutations would not have qualified 
for clinical genetic testing under current guidelines, highlighting the need for expanded inclusion 
criteria for genetic testing in prostate cancer, particularly given the impact of pathogenic 
germline mutations on not only a proband’s own treatment but also cancer screening and 
prevention strategies for his entire family. 
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Abstract 
 
Background: Prostate cancer has a significant heritable component, and rare deleterious 
germline variants in certain genes can increase the risk of prostate cancer. Our aim was to 
describe the prevalence of pathogenic germline variants in cancer predisposing genes in men 
with prostate cancer and at least one additional primary cancer. 
Methods: Using a multi-gene panel, we sequenced germline DNA from 102 men with prostate 
cancer and at least one additional primary cancer who also met one or more of the following 
criteria: 1) age ≤ 55 at diagnosis of first malignancy, 2) rare tumor type or atypical presentation 
of a common tumor, and/or 3) three or more primary malignancies. Cancer family history and 
clinicopathologic data were independently reviewed by a clinical genetic counselor to determine 
if the patient met established criteria for testing for a hereditary cancer syndrome. 
Results: Sequencing identified ~3500 variants. Nine protein truncating deleterious mutations 
were found across six genes including BRCA2, ATM, MLH1, BRIP1, PALB2, and FGFR3. 
Likely pathogenic missense variants were identified in CHEK2 and HOXB13. In total, 11/102 
(10.8%) subjects were found to have pathogenic or likely pathogenic mutations in cancer 
predisposing genes. The majority of these men (64%) did not meet current clinical criteria for 
germline testing.  
Conclusions: Men with prostate cancer and at least one additional primary cancer are enriched 
for harboring a germline deleterious mutation in a cancer predisposing gene that may impact 
cancer prognosis and treatment, but most do not meet current criteria for clinical genetic testing.  
Keywords: prostate cancer, germline variants, multiple primary malignant neoplasms, genetic 
testing, gene panel 
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Introduction 
Prostate cancer has been shown to have a strong heritable component and exhibit 
Mendelian inheritance patterns; however, identification of highly penetrant genes accounting for 
hereditary prostate cancer has proven challenging. To date, there are a limited number of cancer 
predisposition genes that have been definitively shown to increase the risk of prostate cancer. In 
2012, our laboratory identified a recurrent mutation in the HOXB13 gene on chromosome 17 
through linkage analysis.
1
 The HOXB13 G84E mutation is typically on a common haplotype 
consistent with a founder allele and accounts for approximately 5% of all cases of hereditary 
prostate cancer in men of European descent.
2
 Some studies have found evidence that this G84E 
mutation increases the risk of other cancers and is seen more frequently in individuals with 
prostate cancer plus an additional primary cancer.
3-5
 
Prostate cancer is a potential phenotypic manifestation in individuals with germline 
mutations in homologous DNA damage repair genes and individuals with Lynch Syndrome. Men 
in families with hereditary breast and ovarian cancer (HBOC) syndrome and who carry 
deleterious mutations in DNA damage repair genes, including BRCA2, have been observed to 
have an increased risk of prostate cancer and are more likely to have prostate cancer with a 
clinically aggressive phenotype.
6-8
 Multiple recent studies of men with metastatic prostate cancer 
unselected for family history have shown a significant minority of these individuals harbor 
pathogenic or likely pathogenic variants in DNA damage repair genes.
9-11
 Studies have also 
found prostate cancer is increased in individuals with Lynch Syndrome (LS), which classically 
presents as multiple individuals in a family presenting with one or more primary cancers 
including colorectal, small bowel, endometrial, and bladder/ureteral cancers and is due to 
germline mutations in mismatch repair genes.
12,13
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Known cancer susceptibility syndromes now number >100, though mutations in high-
penetrance genes explain only a fraction of heritable cancers.
14
 Common features of hereditary 
cancer syndromes include: early age-of-onset, multiple affected generations, rare tumor types 
and/or multiple primary malignancies. However, hereditary cancers, like sporadic cancers, can 
be heterogeneous in their presentation, pathology, and outcomes. Identifying individuals for 
genetic testing of cancer-susceptibility genes is primarily based on family and personal cancer 
history with a goal of prevention and early detection of cancers in these high-risk populations.  
 Multiple primary malignant neoplasms (MPMNs) (defined as tumors of different 
histology arising in distinct anatomic locations in a single individual) are relatively rare, 
reportedly comprising 6.3% of tumor registry cases.
15
 MPMNs may be synchronous, occurring at 
the same time, or metachronous, occurring greater than six months apart.
16
 Individuals with 
certain cancer syndromes, such as Li-Fraumeni (LF), are well known to carry a particularly high 
risk of developing MPMNs. For example, a study of unselected individuals with sarcoma has 
shown that sarcoma populations overall have a high incidence of pathogenic germline mutations, 
and that those germline carriers in the study were significantly more likely to have MPMN 
phenotype.
17,18
 In addition, a retrospective study of individuals with multiple primary 
malignancies who were referred for clinical genetic testing found 44/111 (39.6%) carried a 
variant in one or more cancer predisposition genes, with DNA mismatch repair genes among the 
most frequently mutated.
19
 While the presence of certain constellations of MPMNs in a single 
individual is considered as one indication for referral for genetic risk assessment, the percentage 
of individuals with MPMNs referred for genetic assessment and the outcomes of clinical genetics 
referrals in these persons with multiple primary cancers has not been extensively described. 
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Given the evidence that rare deleterious mutations in cancer predisposition genes 
contribute to prostate cancer, we set out to determine the frequency of germline mutations in men 
with prostate cancer and at least one additional primary neoplasm. We hypothesized that by 
using a rigorous clinical definition including an MPMN phenotype and early-onset cancers, we 
would increase the likelihood of detecting those individuals with deleterious germline mutations, 
which are able to be passed on and confer cancer risk to subsequent generations. We used a 
multi-gene panel approach which provides the opportunity to sequence the coding regions of 
multiple genes simultaneously via next generation sequencing. 
 
Patients & Methods 
Patient Selection 
 Subjects were selected from the University of Michigan’s Prostate Cancer Genetics 
Project (UM PCGP) and the University of Michigan’s Cancer Genetics Clinic registry (UM 
CGC). Both are approved by the local Institutional Review Board and obtain informed consent 
from each participant. The UM PCGP enrolls men with prostate cancer who have at least one 
living first or second degree relative with prostate cancer, and/or who were diagnosed with 
prostate cancer before age 55 (more than 4,000 consented individuals from 1792 families). The 
UM CGC recruits patients with personal or family history suggestive of hereditary cancer risk 
(approximately 5000 consented individuals from 3800 families). Initial queries of these two 
registries identified 414 men diagnosed with early-onset and/or familial prostate cancer who had 
been diagnosed with at least one additional primary malignancy (excluding non-melanoma skin 
cancer). From these cases, we used the following criteria to further select patients for this study: 
1) early age of onset of first malignancy (<55 years old), 2) diagnosed with rare cancers (e.g., 
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pancreatic cancer, testicular cancer, sarcoma, brain cancer, parathyroid cancer, Hodgkin’s 
lymphoma) and/or 3) three or more primary malignancies in a single individual. Each individual 
patient provided a cancer-family history, which was pathologically confirmed when possible; 
and used to construct a 3 generation pedigree. Individuals who were known carriers of 
pathogenic germline mutations associated with hereditary cancer syndromes were excluded. 
Medical records pertaining to prostate cancer diagnoses were reviewed and prostate cancers were 
categorized as clinically aggressive if they exhibited one of more the following features: Gleason 
sum >7, stage T3b or T4 tumor, pre-diagnosis PSA>15 ng/mL, Gleason score=7 and pre-
diagnosis PSA >10ng/mL, N1 or M1 at diagnosis.  
Personal and family history for each subject was reviewed by a certified genetic 
counselor to determine whether these were suggestive of a hereditary cancer syndrome and 
whether they met published criteria for clinical genetic testing (as defined by the National 
Comprehensive Cancer Network or NCCN using 2015 guidelines for Hereditary Breast Ovarian 
Cancer (HBOC), Li Fraumeni Syndrome (LFS), Lynch Syndrome (LS), PTEN Hamartoma 
Tumor Syndrome (PHTS) or Familial Adenomatous Polyposis (FAP). 
Gene Mutational Analysis  
 Gene mutation profiling was performed on DNA extracted from peripheral blood using 
the Qiagen GeneRead DNAseq Comprehensive Cancer Panel (CCP) consisting of multiplex 
PCR primer sets which amplify >95% of the exonic regions of a panel of genes including genes 
associated with high and moderate penetrance hereditary cancer syndromes as well as genes 
mutated in pathways involved in carcinogenesis of prostate cancer and additional tumor types. 
The majority of samples (94) were typed using the Qiagen GeneRead DNAseq CCP version 2, 
which included 160 genes. The remaining samples (8) were typed using the Qiagen GeneRead 
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DNAseq CCP version 1, which included 124 genes. A list of genes included in each panel is 
found in Supporting Information Table 1. Sequencing was performed on an Illumina HiSeq, and 
analysis of data was performed using the GeneRead Targeted Exon Enrichment Panel Data 
Analysis Portal (http://ngsdataanalysis.sabiosciences.com/NGS2/). In addition, Sanger 
sequencing for the HOXB13 G84E allele was performed on 93/102 subjects in this cohort for 
whom DNA was available, as HOXB13 was not included in either Qiagen gene panel.  
Called variants were annotated with Annovar.
20
 Deleterious, protein-truncating variants 
were identified with putative functional importance preferentially given to stop/loss, frameshift 
insertions/deletions, splice variants. All deleterious and missense variants were referenced for 
pathogenicity using the publically available databases, ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/) and BIC (https://research.nhgri.nih.gov/bic/), and 
established consensus guidelines.
21-23
 Pathogenic and likely pathogenic variants were confirmed 
via Sanger sequencing.  
Statistical Analysis 
 Clinicopathogical characteristics including age at diagnosis of first primary, age at 
diagnosis of prostate cancer, PSA at prostate cancer diagnosis were compared between 
pathogenic germline mutation carriers and non-carriers via two-sided T test. Gleason score, race, 
presence of 3 or more primary malignancies, whether or not patient met NCCN criteria for 
genetic testing of any kind, and the presence of clinically aggressive prostate cancer were 
compared via Fisher’s exact test. P values <0.05 were deemed significantly different.  
 
Results 
Patients 
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 A total of 102 men with prostate cancer, at least one additional primary cancer and 
meeting one or more of three additional inclusion criteria were selected for germline mutation 
profiling (Figure 1). The clinical characteristics of this study population are described in Table 1. 
The mean age at diagnosis of first primary cancer was 51 years and the mean age at prostate 
cancer diagnosis was 53 years. The majority (76/102) of patients had two primary cancers, 22 
had three primary cancers and 4 had four primary cancers. Melanoma was the most common 
additional primary cancer (Supporting Information Table 2). Over half of the men had Gleason 
>7 prostate cancer, and 30% had clinically aggressive prostate cancer. Forty patients (39% of this 
cohort) met criteria for clinical genetic testing of any syndrome based on review of personal and 
family history, with most (38/40) meeting criteria for HBOC.  
Germline Mutational Events 
 In total, over 3500 variants were identified among 102 individuals tested, including 2 
nonsense, 7 frameshift, 5 in-frame coding insertions or deletions, and 525 missense variants. 
Eleven out of 102 (10.8%) men in this study harbored pathogenic or likely pathogenic mutations 
in cancer-predisposing genes. Eight men were found to harbor protein truncating germline 
variants in one of six cancer predisposition genes: BRCA2 (3 cases), ATM (2), MLH1 (1), BRIP1 
(1), PALB2 (1), and FGFR3 (1), with one man harboring deleterious variants in both BRCA2 and 
MLH1 (Table 2). This man had three primary malignancies (prostate cancer, kidney cancer, and 
bladder cancer). Review of 525 missense mutations using Clinvar resulted in the identification of 
two likely pathogenic missense mutations in two men who had the same likely pathogenic 
missense variant in CHEK2. Additional sequencing of the HOXB13 prostate cancer predisposing 
gene in 93/102 men identified two carriers of the known prostate cancer-risk associated G84E 
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allele. One of these G84E carriers also harbored a pathogenic BRCA2 splice variant and had 
three primary malignancies: prostate cancer, liver cancer, and bladder cancer.  
Men who harbored a germline mutation did not differ with respect to age of onset, family 
history, number of primary malignancies, or tumor phenotypes compared to those men who were 
not found to have a deleterious or pathogenic germline mutation from our panel of genes 
(Supporting Information Table 3). Based on expert review of pedigrees using 2015 NCCN 
cancer genetics guidelines, only 4/11 (36%) of the individuals with a pathogenic germline variant 
met criteria for a hereditary cancer syndrome and would have qualified for clinical genetic 
testing based on their personal and/or family history. Three of these four individuals met criteria 
for HBOC testing and harbored pathogenic variants in ATM, BRIP1, and CHEK2 respectively; 
the fourth individual met criteria for HBOC and LS testing and harbored a pathogenic variant in 
both BRCA2 and MLH1. The aforementioned HOXB13 G84E allele and BRCA2 splice variant 
carrier with prostate cancer, liver cancer, and bladder cancer did not meet any criteria for testing. 
 
Discussion 
Among men with prostate cancer and one or more additional primary cancers, we 
identified deleterious or likely pathogenic germline mutations in 10.8% of this selected 
population. Protein truncating variants were found in six genes (BRCA2, ATM, MLH1, BRIP1, 
PALB2, and FGFR3) and a likely pathogenic missense mutation in one gene (CHEK2) from a 
multi-gene panel of 160 selected cancer genes, with the majority of these variants found in genes 
whose function is important for DNA damage repair (DDR). In addition, the prostate cancer risk 
associated HOXB13 G84E allele, which has recently been shown to be associated with an 
increased risk for multiple cancers in a single individual, was found in two individuals with a 
Page 10 of 31Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 
11 
MPMN phenotype.
4
 The most frequently mutated gene in our study was the HBOC gene, 
BRCA2.  The majority (7/11) of the individuals with pathogenic or likely pathogenic germline 
variants did not meet current criteria for clinical genetic testing and thus would likely not have 
been identified as at risk for a hereditary cancer syndrome otherwise. In this pilot study, there 
was no difference in carrier versus non carriers in terms of prostate cancer metastatic disease, 
aggressiveness, or age of onset of prostate cancer. However, as this study selected for early age 
of onset of malignancy as one of the inclusion criteria, it would be difficult to ascertain a 
difference in age of onset in carriers versus non carriers from the study population.  
Prevalence of germline mutations in this selected population of men with prostate cancer 
is similar to rates of 8-17% found in recent studies focusing on the identification of germline 
mutations in men with metastatic prostate cancer unselected for family history
9-11,24
. Also 
similarly, the majority of deleterious variants in our study were in DDR pathway genes.
9-11,24
 
Unique to our study population is that there was no statistical difference in presence of metastatic 
or aggressive disease in mutation carriers, suggesting that patients with multiple primary 
malignancies including prostate cancer may be at increased risk of harboring deleterious 
germline mutations in DDR genes regardless of metastatic disease or gleason score (e.g., Figure 
2). Identifying these men with DDR mutations is now not only important for risk assessment but 
also for treatment given DDR deficient tumors’ sensitivity to platinum-based chemotherapeutics 
and PARP inhibitors.  A phase II study of olaparib in previously treated metastatic prostate 
cancer patients found 6/50 subjects harbored deleterious variants in the DDR-related genes, ATM 
and BRCA2, with all six showing response to PARP inhibition.
9
 In the era of targeted therapies, 
the early identification of a DDR germline mutation in men with prostate cancer and MPMN 
Page 11 of 31 Cancer
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 
12 
phenotype could significantly alter the treatment course and outcomes for these patients’ 
multiple cancers.  
The identification of a risk allele within an individual with cancer also has enormous 
impact for that patient’s family members in regards to risk assessment, cancer screening, and 
cancer prevention. For example, men with BRCA2 germline mutations are known to be at 
increased risk for prostate cancer, and typically display an earlier age of onset of disease and 
aggressive clinical phenotypes.
6,7,25,26
 These high-risk prostate cancer features have led to 
guideline recommendations for prostate cancer screening beginning at age 40 in unaffected 
BRCA2 mutation carriers. Our current study also suggests that use of multigene panel genetic 
tests may be particularly useful in this population given the varied tumor phenotypes, genes 
mutated, and the finding that a majority of the mutation carriers did not meet current NCCN 
guidelines for clinical genetic testing for hereditary cancer syndromes.  For example, as seen in 
the pedigree in Figure 2, a patient with prostate cancer and melanoma was found to harbor a 
deleterious BRCA2 mutation; however, this proband did not meet current clinical criteria for 
germline genetic testing. Upon subsequent testing, this patient’s unaffected brother was also 
found to have this same deleterious BRCA2 mutation. This exemplary finding will alter 
recommendations for cancer screening and treatment for the proband, but also for his at-risk 
relatives, not only for prostate cancer but also other HBOC-associated malignancies.  
Large scale tumor sequencing via comprehensive panels focused on actionable mutations 
is quickly becoming ubiquitous at most comprehensive cancer centers, and the identification of 
germline variants of undetermined significance are an increasing concern. Our study is in line 
with multiple recent studies of germline sequencing in cancer patients showing germline 
aberrations are in general more frequent than previously thought and can be found in patients 
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across age groups and tumor types regardless of family history.
17,27-30
 These studies highlight 
potential shortcomings in current clinical genetic testing practices, which rely primarily on 
constellations of specific personal and family cancer histories to decide whether or not a patient 
should pursue germline mutation testing. Additional parameters independent of family history, 
such as multiple primary cancers, early age of disease onset, and/or rare/aggressive histologies 
may be beneficial to add to the decision algorithm for germline testing in prostate cancer.  
 While the findings of our study are novel, there are limitations including the small sample 
size and the lack of paired somatic sequencing to better determine a pathogenic variant’s impact 
on the tumor(s)’ phenotype. We rely on a germline mutation’s putative functional changes to aid 
in determining its clinical pathogenic impact, which does not always align across tumor types. 
For example, a K3326X stop gain variant in BRCA2 was found in two individuals in this study; 
however, while this variant has been shown to increase the risk of developing breast and/or 
ovarian cancer, its pathogenicity in prostate cancer is less clear and is categorized as benign in 
Clinvar and thus was not included in our pathogenic carrier rate for this study.
31
  In addition, as 
with most large panel whole-exome sequencing studies, there is a high rate of variants of 
unknown significance including missense variants of unknown clinical impact. Given the 
stringent criteria we used selecting for deleterious functional mutations, including restricting 
missense variants to only those referenced with supporting evidence as cancer-associated 
pathogenic or likely pathogenic in Clinvar, our pathogenic or likely pathogenic germline variant 
prevalence in this population may be underestimated. The reported prevalence also does not 
reflect any pathogenic variants harbored in genes not tested in this panel. It should also be noted 
that the vast majority of this selected patient population in the study (~90%) were negative for 
pathogenic or likely pathogenic mutations in the panel of cancer associated genes; in addition, 
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there were individuals who were discovered to have novel mutations or mutations in moderately 
penetrant genes. However, these individuals and their family members may still have an 
increased risk for prostate or other cancers and warrant longitudinal cancer screening. These 
findings highlight the potential clinical and ethical dilemmas for how to best inform patients and 
their families of cancer risk and highlight the necessity of a multidisciplinary approach to genetic 
screening and testing in cancer patients that incorporates genetic counselors, physicians, 
molecular pathology, and psychosocial care for discussing, consenting, performing, and 
interpreting these genetic tests.    
Quantifying and qualifying the prevalence and penetrance of pathogenic germline 
variants in unique subgroups of men with prostate cancer and multiple primary malignancies will 
provide a better understanding of the underlying molecular aberrations involved in the 
pathogenesis of different tumor types, allow for targeted therapeutic approaches, and better 
define high-risk groups that would benefit from early screening and intervention. Our study, 
along with other recent germline studies, have shown that certain clinical populations such as 
those with a MPMN phenotype, early-onset cancer, and/or metastatic/aggressive prostate cancer 
are enriched for germline variants and thus warrant consideration for genetic testing regardless of 
meeting current clinical criteria for hereditary cancer syndromes. However, health insurance 
does not typically cover genetic testing for patients outside of guideline criteria. It is particularly 
important for prostate cancer patients and their families to identify heritable pathogenic variants 
that could prompt prostate screening in unaffected carriers- screening that is otherwise not 
currently recommended in the general US population
32
. Future larger studies to better define risk 
and outcomes in this population of men with prostate cancer and MPMNs who harbor deleterious 
germline variants is warranted. 
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Figure Legends 
 
Figure 1. Venn diagram summarizing the qualifying inclusion criteria of the final cohort of 102 
men. Criteria included: 1) early age of onset of first malignancy (<55 years old), 2) diagnosed 
with rare cancers including pancreatic cancer, sarcoma, male breast cancer and/or 3) three or 
more primary malignancies in a single individual. 
 
Figure 2. Pedigree analysis of proband with BRCA2 q1429fs germline mutation and multiple 
primary malignant neoplasm phenotype. H&N= head & neck cancer. 
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Table 1. Clinical & pedigree features for the cohort of 102 men with prostate cancer and one 
or more additional primary cancers.  
Age at diagnosis in years First Cancer: 51 (5-76) 
Median (range)  Prostate Cancer: 53 (31-84) 
Race Caucasian: 96 (94.1) 
(percentage) African American: 6 (5.9) 
PSA at diagnosis
€
 5.6 (1.0-75.5) 
Median (range)    
Gleason Score  <7: 38 (43.2) 
N (percentage) >7: 50 (56.8) 
Total number of multiple primaries 
 (including prostate cancer) Two primary malignancies: 76 (74.5) 
N (percentage) 
Three primary malignancies: 22 (21.6) 
Four primary malignancies: 4 (3.9) 
Cancer Syndrome Criteria
¶
 None: 62 (60.8) 
N (percentage) Any: 40 (39.2) 
  HBOC: 38 (37.3) 
  LS: 6 (5.9) 
  LF: 2 (2.0) 
Clinically Aggressive Prostate Cancer
£
 31 (30.4) 
N (percentage)   
€
PSA=prostate specific antigen; 
¶
National Comprehensive Cancer Network guidelines for 
clinical genetic testing for: HBOC (hereditary breast and ovarian cancer), LS (Lynch 
syndrome), LF(Li-Fraumeni); 
£
Clinically aggressive prostate cancer defined as meeting one 
of the following criteria: Gleason sum>7, tumor stage T3b or T4, pre-diagnosis 
PSA>15ng/ml, Gleason sum=7 and pre-diagnosis PSA>10ng/ml, N1 or M1 at diagnosis.  
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Table 2. Pathogenic variants in men with prostate cancer and multiple primary 
malignancies 
Gene  Location* 
Variant 
Type 
Allele 
Change 
AA 
Change dbSNP ID
£
 
# 
Carriers 
BRCA2 13 FS
1
 A->AT p.Q1429fs Rs80359440 1 
13 FS T->TA p.Y2215fs Rs80359615 1 
13 SV
2
 A->T p.T3085fs Rs61757642 1 
ATM 11 FS ACT->A p.T761fs Rs587781658 1 
11 SG
3
 T->G p.L1457X Rs373226793 1 
PALB2 16 FS 
GAACAA-
>G p.Q60fs Rs180177143 1 
BRIP1 17 FS AT->A p.N541fs 1 
MLH1 3 FS TAGCC->T p.A661fs 1 
FGFR3 4 FS CAG->C p.D787fs Rs759113408 1 
CHEK2 22 MS
4
 T->C p.I157T Rs17879961 2 
HOXB13 17 MS A->G p.G84E Rs138213197 2 
*Chromosomal location; AA=amino acid; 
£
http://www.ncbi.nlm.nih.gov/projects/SNP/; 
1
frameshift; 
2
splice variant; 
3
stopgain; 
4
missense. 
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Venn diagram summarizing the qualifying inclusion criteria of the final cohort of 102 men. Criteria included: 
1) early age of onset of first malignancy (<55 years old), 2) diagnosed with rare cancers including 
pancreatic cancer, sarcoma, male breast cancer and/or 3) three or more primary malignancies in a single 
individual.  
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Pedigree analysis of proband with BRCA2 q1429fs germline mutation and multiple primary malignant 
neoplasm phenotype. H&N= head & neck cancer.  
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Included in 
Version 1
Included in 
Version 2
ABCC1 yes
ABL1 yes yes
AKT1 yes yes
AKT2 yes
AKT3 yes
ALK yes yes
AMER1 yes
APC yes yes
AR yes
ARID1A yes yes
ARID2 yes
ASXL1 yes yes
ATM yes yes
ATRX yes
BAP1 yes
BCL6 yes
BCOR yes
BRAF yes yes
BRCA1 yes yes
BRCA2 yes yes
BRIP1 yes
BTK yes
BUB1B yes
CARD11 yes yes
CASP8 yes
CBL yes yes
CBLB yes
CD79A yes
CD79B yes
CDC73 yes yes
CDH1 yes yes
CDK12 yes
CDK4 yes
CDKN2A yes yes
CEBPA yes
CHEK2 yes
CIC yes
CREBBP yes yes
CRLF2 yes yes
CSF1R yes yes
CTNNA1 yes
Supporting Information Table 1. 
Genes included in the Qiagen GeneRead 
DNAseq CCP versions 1 and 2. 
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CTNNB1 yes yes
CTSL1 yes
CYLD yes yes
DAXX yes
DDB2 yes
DDR2 yes
DICER1 yes
DNMT3A yes yes
ECT2L yes
EGFR yes yes
EP300 yes yes
EPCAM yes
ERBB2 yes yes
ERBB3 yes
ERBB4 yes yes
ERCC5 yes
ESR1 yes
EZH2 yes yes
FAM123B yes
FAM46C yes
FANCA yes
FANCD2 yes
FANCE yes
FAS yes
FBXO11 yes
FBXW7 yes yes
FGFR1 yes
FGFR2 yes yes
FGFR3 yes yes
FH yes
FIGF yes
FKBP9 yes
FLCN yes
FLT1 yes
FLT3 yes yes
FLT4 yes
FOXL2 yes
FUBP1 yes
GATA1 yes yes
GATA2 yes yes
GATA3 yes
GNA11 yes yes
GNAQ yes yes
GNAS yes yes
GPC3 yes
GRIN2A yes yes
H3F3A yes
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HDAC4 yes
HIST1H3B yes
HNF1A yes yes
HRAS yes yes
HSP90B1 yes
HSPH1 yes
IDH1 yes yes
IDH2 yes yes
IGF2R yes
IKZF1 yes
IL6ST yes
IL7R yes yes
JAK1 yes
JAK2 yes yes
JAK3 yes yes
KDM6A yes yes
KDR yes yes
KIT yes yes
KLF6 yes
KMT2D yes
KRAS yes yes
MAP2K1 yes yes
MAP2K2 yes
MAP2K4 yes yes
MAP3K1 yes
MAP4K3 yes
MDM2 yes
MED12 yes
MEN1 yes yes
MET yes yes
MLH1 yes yes
MPL yes
MSH2 yes yes
MSH6 yes yes
MTOR yes yes
MUTYH yes
MYC yes
MYD88 yes yes
NF1 yes yes
NF2 yes yes
NFE2L2 yes
NFKBIA yes
NOS1 yes
NOTCH1 yes yes
NOTCH2 yes yes
NPM1 yes yes
NRAS yes yes
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NTN3 yes
PALB2 yes
PARP1 yes
PARP4 yes
PAX5 yes yes
PBRM1 yes
PDGFRA yes yes
PDGFRB yes
PHF6 yes
PIK3C2A yes
PIK3CA yes yes
PIK3R1 yes yes
PIK3R5 yes
PMS2 yes
POLR3A yes
PPP2R1A yes yes
PRDM1 yes
PRKAR1A yes yes
PRKCE yes
PTCH1 yes yes
PTEN yes yes
PTGS2 yes
PTPN11 yes yes
PTPRC yes
RAC1 yes
RB1 yes yes
RET yes yes
ROS1 yes yes
RUNX1 yes
SDHB yes
SETD2 yes yes
SF3B1 yes
SLC7A8 yes
SMAD2 yes
SMAD4 yes yes
SMARCA4 yes yes
SMARCB1 yes yes
SMO yes yes
SOCS1 yes
SPOP yes
SRC yes yes
STK11 yes yes
SUFU yes
TERT yes yes
TET2 yes
TGFBR2 yes
TNFAIP3 yes yes
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TNFRSF14 yes
TNKS yes
TOP1 yes
TP53 yes yes
TRRAP yes
TSC1 yes
TSC2 yes
TSHR yes yes
U2AF1 yes
VHL yes yes
WT1 yes yes
XPC yes
XPO1 yes
ZNF2 yes
ZRSR2 yes
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Supporting Information Table 2. Additional primary cancers in the cohort of 102 men with prostate 
cancer. 
Additional Primary Cancers Number of Subjects 
Atypical fibrous histiocytoma 1 
Bladder 6 
Bladder & Colon 1 
Bladder & Esophageal 1 
Bladder & Kidney 3 
Bladder & Liver 2 
Bladder & Lung 2 
Bladder & Lymphoma 1 
Bladder & Melanoma 1 
Bone 1 
Brain 2 
Brain-Glioblastoma & Melanoma 1 
Carcinoid, small bowel 1 
Colon 5 
Colon & Vocal cord 1 
Colon/rectum & Lung 1 
Esophagus 3 
Esophagus & Pancreas 1 
Head and Neck 5 
Head and Neck & Lung 1 
Head and Neck (2 primaries) & Thyroid 1 
Head and Neck & Sarcoma 1 
Hodgkins 1 
Kidney 5 
Kidney & Melanoma 1 
Liposarcoma 1 
Lung 4 
Lung & Melanoma & Sarcoma 1 
Lung & Melanoma & Pancreas  1 
Lymphoma 1 
Lymphoma & Renal cancer 1 
Mantle cell & Thyroid 1 
Melanoma 28 
Melanoma & Renal cancer  1 
Pancreas 4 
Parathyroid 1 
Renal cancer & Sarcoma (2 primaries) 1 
Renal cancer & Thyroid 1 
Testicular 4 
Thyroid 3 
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Supporting Information Table 3. Clinicopathologic characteristics of mutation carriers 
versus non-carriers. 
  
All Samples  
(N=102) 
Carriers  
(N=11) 
Non 
Carriers  
(N=91) 
P Value 
Age at Dx of Prostate Cancer 
(median/range) 
53 (31-84) 54 (46-71) 53 (31-84) 0.8750* 
Pre-Dx PSA*** (median/range) 
5.55 (1-
75.56) 
5.5 (3.47-
21.4) 
5.6 (1-
75.56) 
0.6498* 
Gleason Score (N/%)****         
<7 38 (43.2) 6 (54.5) 31(40.2) 0.5158** 
7 43 (48.9) 4 (36.4) 40 (51.9)   
>7 7 (8.0) 1 (9.1) 6 (7.8)   
Ancestry (N/%)         
European 96 (94.1) 10 (90.9) 86 (94.5) 0.5050** 
African 6 (5.9) 1 (9.1) 5 (5.5)   
Clinically Aggressive PC (N/%)         
Yes 31 (30.4) 4 (36.4) 27 (29.7) 0.7316** 
No 71 (69.6) 7 (63.6) 64 (70.3)   
Number of Cancers (N/%)         
2 76 (74.5) 7 (63.6) 69 (75.8) 0.4649** 
3 or more 26 (25.5) 4 (36.4) 22 (24.2)   
Criteria for Clinical Testing 
(N/%) 
        
Yes 40 (39.2) 4 (36.4) 35 (38.5) 1** 
No 62 (60.8) 7 (63.6) 56 (61.5)   
*Two sided t-test; **Fisher’s exact test; ***N=83 total samples with available pre-
diagnosis PSA; ****N=88 total samples with available Gleason score.  
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